Table 1. Characteristics and indicators of W. bancrofti endemicity levels in all the sites where ICT and FTS were used in parallel in subjects.
| Country& | District | MDA$ | N | Median age (IQR) |
Males (%) |
No. ICT+ (%) |
No. FTS+ (%) |
FTS/ICT Ratio |
No. ICT+/FTS- |
No. Mf+ (%)* |
GM (95% CI)* |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liberia | Total | IVM+ALB | 1,830 | 18 (10–40) | 51.1 | 285 (15.6) | 315 (17.2) | 1.11 | 2 | 41 (16.8) | 162.4 (102.2–257.9) |
| Foya | IVM+ALB | 681 | 14 (8–35) | 48.5 | 78 (11.5) | 81 (11.9) | 1.04 | 2 | 0 | NA | |
| Harper | IVM+ALB | 1,149 | 22 (10–42) | 52.6 | 207 (18.0) | 234 (20.4) | 1.13 | 0 | 41 (25.0) | 162.4 (102.2–257.9) | |
| Côte d'Ivoire | Lagunes | No | 968 | 29 (15–47) | 35.8 | 254 (26.2) | 263 (27.2) | 1.04 | 11 | 79 (30.4) | 227.8 (164.0–316.6) |
| Congo | Bouenza | ALB | 697 | 24 (10–43) | 46.7 | 44 (6.3) | 85 (12.2) | 1.93 | 1 | 10 (11.9) | 27.8 (13.4–57.5) |
| DRC | Kwilu | No | 187 | 15 (10–35) | 44.9 | 29 (15.5) | 42 (22.5) | 1.45 | 0 | 18 (42.9) | 302.2 (105.1–869.0) |
| Total Pre-MDA | - | 1,155 | 28 (14–45) | 37.3 | 283 (24.5) | 305 (26.4) | 1.08 | 11 | 97 (32.1) | 240.1 (173.9–331.5) | |
| Total Post-MDA | - | 2,527 | 20 (10–40) | 49.9 | 329 (13.0) | 400 (15.8) | 1.22 | 3 | 51 (15.6) | 114.8 (74.2–177.7) | |
| Total all sites | NA | 3,682 | 23 (11–42) | 45.9 | 612 (16.6) | 705 (19.2) | 1.15 | 14 | 148 (23.5) | 186.2 (143.2–242.2) | |
| Sri Lanka | DEC+ALB | 852 | 18 (2.1) | 43 (5.1) | 2.43 | 0 | - | - | |||
| Indonesia | DEC+ALB | 778 | 41 (5.3) | 50 (6.4) | 1.21 | 3 | - | - |
DRC = Democratic Republic of Congo; MDA = Mass Drug Administration; ALB = albendazole; IVM = ivermectin; N = number of subjects examined; IQR = Inter-quartile range; ICT+ = positive at the ICT test; FTS+ = positive at the FTS test; Mf+ = microfilaremic; GM = Geometric mean microfilarial density (Mf/mL) among the microfilaremic individuals; 95%CI = 95% Confidence Interval; NA = not applicable.
& Liberia, Côte d'Ivoire, Congo, and DRC (new data included in this paper); Sri Lanka and Indonesia (data already published) [9].
$ Four MDA rounds both for Liberia and Congo sites.
* Percentage of microfilaremic individuals and GM among those with positive FTS.